First AD

Second AD

The panel discusses the biologic drugs approved for use in children with asthma.

Biologic Options in Pediatric Asthma

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Allergies, Asthma Exacerbations and Uncontrolled Asthma Management

The panel discusses the biologic drugs approved for use in children with asthma, including omalizumab, dupilumab, mepolizumab, and the recently approved benralizumab. They share their preferences among these options for improving lung function in pediatric patients.

External Factors and Seasonality of Asthma

Endotypes and Phenotypes in Asthma

Type 2 Inflammation and Biomarkers in Asthma

Moderate/Severe/Uncontrolled Asthma Classification

Thinking About Endotypes when Managing Asthma

Use of Oral Corticosteroids in Asthma

High Oral Corticosteroid Dose and Exposure in Asthma

Oral Corticosteroid Overuse and Uncontrolled Asthma

Biomarkers and Eosinophil Levels in Severe or Uncontrolled Asthma

Biologics in Asthma

GINA Guidelines and Biologics for Treatment of Asthma

Use of Biologics for Asthma in Patients with Allergies

Treatment of Asthma in Pediatric Patients

Atopic March in Pediatric Patients

Use of Biologics in Pediatric Patients and Conversations with Parents

Advice for Clinicians Managing Asthma